Tengion boosted by restart of Neo-Urinary Conduit trial
This article was originally published in Clinica
Executive Summary
Regenerative medicine specialist Tengion finally has something to cheer about – it has resumed patient enrolment for a Phase I trial of its lead product, the Neo-Urinary Conduit, after the US FDA approved changes made to the procedure for implanting the device. The product is being evaluated in bladder cancer patients requiring a urinary diversion after their bladder has been removed.